V. Kouranos (London, United Kingdom), M. Bonifazi (Ancona (AN), Italy), E. Bargagli (Siena, Italy), V. Alfieri (Parma (PR), Italy)
Introduction of a new approach to interpret pulmonary function tests (PFT) based on Machine learning and Game theory
N. LE-DONG (Paris, France), T. Hua-Huy (Paris, France), M. Topalovic (Leuven, Belgium), A. Dinh-Xuan (Paris, France)
|  |
A translational value of pulmonary function tests in a mouse model of bleomycin-induced pulmonary fibrosis: effects of approved therapies Nintedanib and Pirfenidone
Ž. Anzulovic (Zagreb, Croatia), M. Antolic (Zagreb, Croatia), A. Ognjenovic (Zagreb, Croatia), S. Cužic (Zagreb, Croatia), I. Glojnaric (Zagreb, Croatia), B. Hrvacic (Zagreb, Croatia)
|  |
A comparison of existing questionnaires for identifying the causes of interstitial and rare lung diseases
M. Polke (Germany), D. Kirsten (Schleswig-Holstein, Germany), B. Teucher (Heidelberg, Germany), U. Costabel (Essen, Germany), F. Herth (Heidelberg, Germany), M. Kreuter (Heidelberg, Germany)
| |
Transbronchial Cryobiopsy Validity in Diagnosing Indefinite Usual Interstitial Pneumonia in High Resolution Computed Tomography in Egyptian Population
H. Shafiek (Alexandria, Egypt), S. Elbialy (Alexandria, Egypt), S. Elachy (Alexandria, Egypt), A. Gad (Alexandria, Egypt)
| |
Predictors of pulmonary-functional decline in systemic sclerosis: A university hospital experience
E. Vallejos (Buenos Aires, Argentina), F. Felder (Buenos Aires, Argentina), S. Leiva (Buenos Aires, Argentina), J. Enghelmayer (Buenos Aires, Argentina), R. Gómez (Buenos Aires, Argentina), P. Rossi (Buenos Aires, Argentina), F. Zenón (Buenos Aires, Argentina), G. Legarreta (Buenos Aires, Argentina), S. Acuña (Buenos Aires, Argentina), M. Volpacchio (Buenos Aires, Argentina)
| |
Dose adjustments in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)
K. Highland (Cleveland, Ohio, United States of America), M. Kuwana (Tokyo, Japan), A. Azuma (Tokyo, Japan), A. Fischer (Denver, Colorado, United States of America), T. Maher (London, United Kingdom), M. Mayes (Houston, Texas, United States of America), G. Raghu (Seattle, United States of America), M. Girard (Reims, France), V. Kohlbrenner (Ridgefield, Connecticut , United States of America), E. Clerisme-Beaty (Ingelheim am Rhein, Germany), M. Alves (Ingelheim am Rhein, Germany), O. Distler (Zurich, Switzerland)
| |
Longitudinal cost of care in individuals with different subtypes of interstitial lung diseases
L. Schwarzkopf (Neuherberg, Germany), S. Witt (Neuherberg, Germany), J. Wälscher (Heidelberg, Germany), M. Kreuter (Heidelberg, Germany)
| |
Antifibrotic treatment in 18 patients with chronic Hypersensitivity Pneumonitis
V. Tzilas (Athens, Greece), A. Tzouvelekis (Athens, Greece), E. Bouros (Athens, Greece), M. Katsaras (Athens, Greece), M. Ntassiou (Athens, Greece), T. Karampitsakos (Athens, Greece), D. Bouros (Athens, Greece)
| |
Evaluation of drug-induced lung injury by ALK inhibitor: a single center retrospective analysis
K. Koshikawa (Chiba, Japan), J. Terada (Chiba, Japan), M. Abe (Chiba, Japan), S. Iwasawa (Chiba, Japan), M. Sakayori (Chiba, Japan), K. Tsushima (Narita, Japan), K. Tatsumi (Chiba, Japan)
| |
A comparison of heath-related quality of life in IPF and systemic sclerosis-related ILD
T. Sjåheim (Oslo, Norway), A. Hoffman-Vold (Oslo, Norway), T. Eagan (Bergen, Norway), A. Hovden (Asker, Norway), M. Lund (Oslo, Norway), G. Bjerke (Lørenskog, Norway), T. Jonassen (Bergen, Norway), O. Johansen (Asker, Norway), M. Durheim (Oslo, Norway)
| |
Hypersensitivity Pneumonitis in North Indian population
A. Sinha (Ghaziabad, India)
| |
A Combined Rheumatology/ILD Service. The Wolverhampton Experience
A. Zahid (Stoke-on-Trent, United Kingdom), P. Chohan (Wolverhampton, United Kingdom), T. Sheeran (Wolverhampton, United Kingdom), A. Fahim (Wolverhampton, United Kingdom)
| |
Acute exacerbation admissions of fibrosing interstitial lung diseases – 3 years study
S. Silva Guerra (Viseu, Portugal), M. Conceição (Viseu, Portugal), Â. Cunha (Viseu, Portugal), J. Correia (Viseu, Portugal), J. Vale (Viseu, Portugal), C. António (Viseu, Portugal), A. Simões Torres (Viseu, Portugal)
| |
An observational study on effectiveness of azathioprine in treatment of interstitial lung disease secondary to connective tissue disease
M. Saeidinejad (Wigan, United Kingdom), S. Gnanalingam (Wigan, United Kingdom), A. Ashish (Wigan, United Kingdom)
| |
The potential role of antimicrobial peptides from wasp as regulators of the fibrotic process in idiopathic pulmonary fibrosis.
L. Coutinho Coelho (Brasília, Brazil), K. Smidt Simon (Brasília, Brazil), C. Augusto Melo-Silva (Brasília, Brazil), P. De Holanda Veloso Junior (Brasília, Brazil), J. Figueiró Longo (Brasília, Brazil), L. Maciel Sousa Vianna (Brasília, Brazil), V. Moreira Amado (Brasília, Brazil), M. Renata Mortari (Brasília, Brazil), A. Lorenzetti Bocca (Brasília, Brazil)
| |
Features and functional deterioration in interstitial lung disease (ILD) asociated to rheumatoid arthritis (RA)
M. Nieto Barbero (M, Spain), C. Vadillo (M, Spain), F. Pelaez (M, Spain), A. Palomar (M, Spain), L. Abasolo (M, Spain)
| |
The role of Surgical Lung Biopsy in Interstitial Lung Diseases. Is it mandatory in this time of multiple diagnostic procedures? Analysis of 186 patients surgically treated.
S. Sanna (Forli, Italy), D. Argnani (Forli, Italy), M. Mengozzi (Forli, Italy), A. Parisi (Forli, Italy), S. Tommasetti (Forli, Italy), V. Poletti (Forli, Italy), F. Stella (Forli, Italy)
| |
Multicentric Latin American study of 211 patients with Interstitial lung disease and myositis related antibodies
F. Reyes (Santiago, Chile), V. Wolff (Santiago, Chile), L. Alberti (Buenos Aires, Argentina), E. Juarez (Mexico DF, Mexico), V. Leiva (Santiago, Chile), L. Fassola (Buenos Aires, Argentina), M. Mejia (Mexico DF, Mexico), I. Buendia (Mexico DF, Mexico), F. Caro (Buenos Aires, Argentina), J. Rojas Serrano (Mexico DF, Mexico), F. Paulin (Buenos Aires, Argentina), M. Florenzano (Santiago, Chile)
| |